The IPO for Medicamen Organics is a book-built issue amounting to Rs 10.54 crores. This offering consists solely of a fresh issue totaling 31 lakh shares.
The subscription period for the Medicamen Organics IPO starts on June 21, 2024, and ends on June 25, 2024. The share allotment is anticipated to be finalized on Wednesday, June 26, 2024, and the shares are expected to be listed on the NSE SME on Friday, June 28, 2024.
The IPO price range for Medicamen Organics is set between ₹32 and ₹34 per share. Investors must apply for a minimum of 4000 shares per lot, requiring at least ₹136,000 for a retail investment. High Net Worth Individuals (HNIs) must invest in a minimum of 2 lots, or 8,000 shares, which amounts to ₹272,000.
Medicamen Organics IPO Details
| IPO Date | June 21, 2024 to June 25, 2024 |
| Listing Date | [.] |
| Face Value | ₹10 per shar |
| Price Band | ₹32 to ₹34 per share |
| Lot Size | 4000 Shares |
| Total Issue Size | 3,100,000 shares (aggregating up to ₹10.54 Cr) |
| Fresh Issue | 3,100,000 shares (aggregating up to ₹10.54 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | NSE SME |
| Share holding pre issue | 8,600,000 |
| Share holding post issue | 11,700,000 |
| Market Maker portion | 172,000 shares |
Medicamen Organics IPO Lot Size
| Application | Lots | Shares | Amount |
| Retail (Min) | 1 | 4000 | ₹136,000 |
| Retail (Max | 1 | 4000 | ₹136,000 |
| HNI (Min) | 2 | 8000 | ₹272,000 |
Medicamen Organics IPO Objectives
The company intends to allocate the Net Proceeds from the Issue to the following purposes:
- Covering the costs associated with registering products in international markets.
- Updating the plant and enhancing production capacity.
- Meeting the company’s working capital needs.
- General corporate purposes
About Medicamen Organics Limited
Incorporated in 1995, Medicamen Organics Limited specializes in developing, manufacturing, and distributing pharmaceutical dosages, including generic forms such as tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders. The company serves both governmental bodies and private entities as a contract and third-party manufacturer.
Medicamen Organics Limited offers an extensive product range of 84 items, encompassing various drug categories such as antibacterial, antidiarrheal, antifungal, antimalarial, antidiabetic, proton pump inhibitors, antihistamines, antihypertensive drugs, lipid preparations, antiparasitics, multivitamin preparations, multimineral, and non-steroidal anti-inflammatory drug (NSAIDs).
Medicamen Organics Limited Financial Information
| Period Ended | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
| Assets | 3,858.07 | 3,211.98 | 2,707.21 | 2,634.37 |
| Revenue | 2,528.96 | 2,296.24 | 2,118.67 | 2,505.96 |
| Profit After Tax | 240.41 | 95.78 | 9.23 | 29.81 |
| Net Worth | 1,518.40 | 851.71 | 755.92 | 746.72 |
| Reserves and Surplus | 658.40 | 251.71 | 155.92 | 146.72 |
| Total Borrowing | 1,265.65 | 1,179.50 | 1,024.57 | 958.97 |
Medicamen Organics IPO Timeline
| IPO Open Date | Friday, June 21, 2024 |
| IPO Close Date | Tuesday, June 25, 2024 |
| Basis of Allotment | Wednesday, June 26, 2024 |
| Initiation of Refunds | Thursday, June 27, 2024 |
| Credit of Shares to Demat | Thursday, June 27, 2024 |
| Listing Date | Friday, June 28, 2024 |
| Cut-off time for UPI mandate confirmation | 5 PM on June 25, 2024 |
Conclusion
Medicamen Organics Limited, established in 1995, is a prominent player in the pharmaceutical industry, specializing in the development, manufacture, and distribution of a wide array of generic pharmaceutical dosages. With a comprehensive product lineup and a robust distribution network across India and several international markets, the company serves both government and private sectors. The upcoming IPO aims to support the company’s growth initiatives, including product registration in international markets, plant upgrades, increased production capacity, working capital needs, and general corporate purposes
